Genital Neoplasms, Female  >>  Lynparza (olaparib)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lynparza (olaparib) / Merck (MSD), AstraZeneca
NCT02392676: Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Withdrawn
3
0
US, Europe, RoW
OLAPARIB, PLACEBO
AstraZeneca, Myriad Genetic Laboratories, Inc.
Platinum Sensitive Relapsed Ovarian Cancer
06/19
06/19

Download Options